DE69832092D1 - VERBESSERTE HMG CoA REDUKTASE-INHIBITOR FORMULIERUNG MIT VERLÄNGERTER FREISETZUNG - Google Patents

VERBESSERTE HMG CoA REDUKTASE-INHIBITOR FORMULIERUNG MIT VERLÄNGERTER FREISETZUNG

Info

Publication number
DE69832092D1
DE69832092D1 DE69832092T DE69832092T DE69832092D1 DE 69832092 D1 DE69832092 D1 DE 69832092D1 DE 69832092 T DE69832092 T DE 69832092T DE 69832092 T DE69832092 T DE 69832092T DE 69832092 D1 DE69832092 D1 DE 69832092D1
Authority
DE
Germany
Prior art keywords
improved
coa reductase
extended release
reductase inhibitor
hmg coa
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69832092T
Other languages
English (en)
Other versions
DE69832092T2 (de
Inventor
Chih-Ming Chen
Joseph Chou
David Wong
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Andrx Pharmaceuticals LLC
Original Assignee
Andrx Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Andrx Pharmaceuticals LLC filed Critical Andrx Pharmaceuticals LLC
Publication of DE69832092D1 publication Critical patent/DE69832092D1/de
Application granted granted Critical
Publication of DE69832092T2 publication Critical patent/DE69832092T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DE69832092T 1997-12-12 1998-12-04 VERBESSERTE HMG CoA REDUKTASE-INHIBITOR FORMULIERUNG MIT VERLÄNGERTER FREISETZUNG Expired - Lifetime DE69832092T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/989,253 US5916595A (en) 1997-12-12 1997-12-12 HMG co-reductase inhibitor
US989253 1997-12-12
PCT/US1998/025766 WO1999030692A1 (en) 1997-12-12 1998-12-04 IMPROVED HMG CoA REDUCTASE INHIBITOR EXTENDED RELEASE FORMULATION

Publications (2)

Publication Number Publication Date
DE69832092D1 true DE69832092D1 (de) 2005-12-01
DE69832092T2 DE69832092T2 (de) 2006-07-13

Family

ID=25534912

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69832092T Expired - Lifetime DE69832092T2 (de) 1997-12-12 1998-12-04 VERBESSERTE HMG CoA REDUKTASE-INHIBITOR FORMULIERUNG MIT VERLÄNGERTER FREISETZUNG

Country Status (9)

Country Link
US (1) US5916595A (de)
EP (1) EP1035842B1 (de)
JP (2) JP4646400B2 (de)
AT (1) ATE307572T1 (de)
AU (1) AU737962B2 (de)
CA (1) CA2315329C (de)
DE (1) DE69832092T2 (de)
ES (1) ES2252872T3 (de)
WO (1) WO1999030692A1 (de)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060141036A1 (en) * 1997-12-12 2006-06-29 Andrx Labs Llc HMG-CoA reductase inhibitor extended release formulation
US6245357B1 (en) * 1998-03-06 2001-06-12 Alza Corporation Extended release dosage form
US8524277B2 (en) * 1998-03-06 2013-09-03 Alza Corporation Extended release dosage form
SE9801429D0 (sv) * 1998-04-23 1998-04-23 Siemens Elema Ab Förgasare
US6569461B1 (en) * 1999-03-08 2003-05-27 Merck & Co., Inc. Dihydroxy open-acid and salts of HMG-CoA reductase inhibitors
EP1036563A1 (de) * 1999-03-08 2000-09-20 MERCK & CO. INC. Dihydroxy offen Saüre und Salzen von hmg-coa reductase Inhibitoren
AU2866400A (en) * 1999-03-08 2000-09-28 Merck & Co., Inc. Dihydroxy open-acid and salts of hmg-co-a reductase inhibitors
SE9903879D0 (sv) * 1999-10-28 1999-10-28 Ethical Pharmaceuticals Sweden Multipor food protection
KR20020063174A (ko) * 1999-11-03 2002-08-01 하워드 제이 스미스 앤드 어쏘시에이츠 피티와이 엘티디 간의 선택적 치료방법
US20020107173A1 (en) * 1999-11-04 2002-08-08 Lawrence Friedhoff Method of treating amyloid beta precursor disorders
EP1225880A2 (de) * 1999-11-04 2002-07-31 Andrx Corporation Verwendung von einem hgm coa-reduktase inhibitor zur behandlung von amyloid-beta-precursor störungen
KR100748913B1 (ko) * 1999-11-22 2007-08-13 알자 코포레이션 제 1 및 제 2 를 함유하는 삼투성 투약 형태
US20060153914A1 (en) * 1999-12-10 2006-07-13 Biovail Laboratories International S.R.L. Chronotherapeutic diltiazem formulations and the administration thereof
US6419956B1 (en) 1999-12-30 2002-07-16 Ancile Pharmaceuticals Odor-masking coating for a pharmaceutical preparation
JP2003521507A (ja) 2000-02-04 2003-07-15 ディポメド，インコーポレイティド ゼロ次薬物放出に接近するシェル−コア剤形
US6759142B2 (en) * 2001-07-31 2004-07-06 Kobe Steel Ltd. Plated copper alloy material and process for production thereof
US20030091630A1 (en) * 2001-10-25 2003-05-15 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data
CA2409552A1 (en) 2001-10-25 2003-04-25 Depomed, Inc. Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
US20030104052A1 (en) * 2001-10-25 2003-06-05 Bret Berner Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
US20030152622A1 (en) * 2001-10-25 2003-08-14 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral diuretic
US6635675B2 (en) 2001-11-05 2003-10-21 Cypress Bioscience, Inc. Method of treating chronic fatigue syndrome
US6602911B2 (en) 2001-11-05 2003-08-05 Cypress Bioscience, Inc. Methods of treating fibromyalgia
US6967218B2 (en) * 2002-01-11 2005-11-22 Biovail Laboratories, Inc. Pravastatin pharmaceutical formulations and methods of their use
EP1905431A1 (de) * 2002-01-11 2008-04-02 Circ Pharma Research and Development Limited Pharmazeutische Pravastatin-Formulierungen und Verfahren zu ihrer Verwendung
DE10209979A1 (de) * 2002-03-07 2003-09-25 Ratiopharm Gmbh Arzneimittel mit Cholesterolspiegel-senkenden Wirkstoffen mit zeitverzögerter Wirkstofffreisetzung
CA2379887C (en) * 2002-04-09 2004-01-20 Bernard Charles Sherman Stable tablets comprising simvastatin
TW200404544A (en) * 2002-06-17 2004-04-01 Kowa Co Controlled release pharmaceutical composition
US20040132806A1 (en) * 2002-09-03 2004-07-08 Jackie Butler Pravastatin pharmaceutical formulations and methods of their use
ZA200501508B (en) * 2002-09-03 2006-10-25 Biovail Lab Inc Pharmaceuticals formulations and methods for modified release of statin drugs
SI21400A (sl) * 2003-02-12 2004-08-31 LEK farmacevtska družba d.d. Stabilna farmacevtska oblika z inhibitorjem HMG-CoA reduktaze
MXPA05009976A (es) * 2003-03-17 2005-11-04 Japan Tobacco Inc Metodo para incrementar la biodisponibilidad oral del 2-metilpropantioato de s-[2-([[1- 2-etilbutil) ciclohexil] carbonil] amino) fenilo].
EP2289507A1 (de) * 2003-03-17 2011-03-02 Japan Tobacco, Inc. Pharmazeutische CETP-Inhibitor-Zubereitungen
TWI393560B (zh) * 2003-05-02 2013-04-21 Japan Tobacco Inc 包含ｓ-〔２（〔〔１-（２-乙基丁基）環己基〕羰基〕胺基）苯基〕２-甲基丙烷硫酯及ｈｍｇ輔酶ａ還原酶抑制劑之組合
US8987322B2 (en) * 2003-11-04 2015-03-24 Circ Pharma Research And Development Limited Pharmaceutical formulations for carrier-mediated transport statins and uses thereof
MY147202A (en) * 2003-11-26 2012-11-14 Novartis Ag Compositions comprising organic compounds
KR100598326B1 (ko) 2004-04-10 2006-07-10 한미약품 주식회사 ＨＭＧ-ＣｏＡ 환원효소 억제제의 경구투여용 서방형 제제및 이의 제조방법
EP1748761A4 (de) * 2004-05-27 2011-10-12 Dexcel Pharma Technologies Ltd Lokalisierte kontrollierte absorption von statinen im gastrointestinaltrakt zur erzielung hoher statinspiegel im blut
US20050287185A1 (en) * 2004-06-23 2005-12-29 David Wong Extended release oxybutynin formulation
US20060078615A1 (en) * 2004-10-12 2006-04-13 Boehringer Ingelheim International Gmbh Bilayer tablet of telmisartan and simvastatin
AU2005305459A1 (en) * 2004-11-22 2006-05-26 Dexcel Pharma Technologies Ltd. Controlled absorption of statins in the intestine
AU2006228525A1 (en) * 2005-03-28 2006-10-05 Dexcel Pharma Technologies Ltd. Controlled absorption of statins in the intestine
AU2006263337A1 (en) * 2005-06-29 2007-01-04 Panacea Biotec Ltd. Modified release pharmaceutical compositions on the basis of two polymers and processes thereof
US7994220B2 (en) * 2005-09-28 2011-08-09 Cypress Bioscience, Inc. Milnacipran for the long-term treatment of fibromyalgia syndrome
US20070098746A1 (en) * 2005-11-02 2007-05-03 Nichols William M Multi-layered coating technology for taste masking
US8440695B2 (en) * 2005-11-09 2013-05-14 St Jude Children's Research Hospital Use of chloroquine to treat metabolic syndrome
US8124598B2 (en) * 2006-09-14 2012-02-28 Sharon Sageman 7-keto DHEA for psychiatric use
EP2079448A2 (de) * 2006-10-10 2009-07-22 Dexcel Pharma Technologies Ltd. Verbesserte freisetzung von statinen im darm
US20100160274A1 (en) * 2007-09-07 2010-06-24 Sharon Sageman 7-KETO DHEA for Psychiatric Use
MX2011001384A (es) 2008-08-06 2011-09-27 Gosforth Ct Holdings Pty Ltd Composiciones y metodos para tratar trastornos psiquiatricos.
EP2516926B1 (de) * 2009-12-22 2017-03-29 Accordant Energy, LLC Gemischte brennstoffe enthaltend sorptionsmittel
CN102670557A (zh) * 2011-03-14 2012-09-19 北京天衡药物研究院 洛伐他汀渗透泵型控释片
GB201111712D0 (en) 2011-07-08 2011-08-24 Gosforth Ct Holdings Pty Ltd Pharmaceutical compositions
US20130143867A1 (en) 2011-12-02 2013-06-06 Sychroneuron Inc. Acamprosate formulations, methods of using the same, and combinations comprising the same
AR089765A1 (es) * 2012-01-23 2014-09-17 Bayer Oy Un sistema para el suministro de un farmaco
CN104069502B (zh) 2013-03-29 2018-02-16 北京罗诺强施医药技术研发中心有限公司 复合骨架材料及其药物组合物
CN105431144A (zh) 2013-06-05 2016-03-23 思康脑侒股份有限公司 阿坎酸制剂、使用阿坎酸制剂的方法以及包含阿坎酸制剂的组合
US20150133516A1 (en) 2013-11-13 2015-05-14 Brian K. Adams Methods and Compositions for Treating ADHD
AU2016288643A1 (en) 2015-07-02 2018-02-22 University Of Louisville Research Foundation, Inc. Edible plant-derived microvesicle compositions for delivery of miRNA and methods for treatment of cancer
US11491114B2 (en) * 2016-10-12 2022-11-08 Curioralrx, Llc Formulations for enteric delivery of therapeutic agents

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5366738A (en) * 1982-07-29 1994-11-22 Merck & Co., Inc. Controlled release drug dispersion delivery device
GB8518301D0 (en) * 1985-07-19 1985-08-29 Fujisawa Pharmaceutical Co Hydrodynamically explosive systems
US4814183A (en) * 1987-08-31 1989-03-21 Merck & Co., Inc. Device for the controlled release of drugs with Donnan-like modulation by charged insoluble resins
US4976967A (en) * 1987-08-03 1990-12-11 Merck & Co., Inc. Resin modulated drug delivery device for the delivery of HMG-CoA reductase inhibitor salts
US4915954A (en) * 1987-09-03 1990-04-10 Alza Corporation Dosage form for delivering a drug at two different rates
US4946686A (en) * 1987-09-24 1990-08-07 Merck & Co., Inc. Solubility modulated drug delivery system
FR2655266B1 (fr) * 1989-12-05 1992-04-03 Smith Kline French Lab Compositions pharmaceutiques a base de cimetidine.
US5300288A (en) * 1991-04-05 1994-04-05 Rohm And Haas Company Composition and method for controlling cholesterol
US5543154A (en) * 1991-12-27 1996-08-06 Merck & Co., Inc. Controlled release nifedipine delivery device
US5244916A (en) * 1992-01-31 1993-09-14 The Scripps Research Institute Inhibition of respiratory burst using posttranslational modification inhibitors
US5518730A (en) * 1992-06-03 1996-05-21 Fuisz Technologies Ltd. Biodegradable controlled release flash flow melt-spun delivery system
US5350584A (en) * 1992-06-26 1994-09-27 Merck & Co., Inc. Spheronization process using charged resins
US5260069A (en) * 1992-11-27 1993-11-09 Anda Sr Pharmaceuticals Inc. Pulsatile particles drug delivery system
US5358502A (en) * 1993-02-25 1994-10-25 Pfizer Inc PH-triggered osmotic bursting delivery devices
IN176897B (de) * 1993-10-29 1996-09-28 Cadila Lab Ltd
US5582838A (en) * 1994-12-22 1996-12-10 Merck & Co., Inc. Controlled release drug suspension delivery device
US5558879A (en) * 1995-04-28 1996-09-24 Andrx Pharmaceuticals, Inc. Controlled release formulation for water soluble drugs in which a passageway is formed in situ
US5654005A (en) * 1995-06-07 1997-08-05 Andrx Pharmaceuticals, Inc. Controlled release formulation having a preformed passageway
JP3134187B2 (ja) * 1996-03-07 2001-02-13 武田薬品工業株式会社 放出制御組成物
US5837379A (en) * 1997-01-31 1998-11-17 Andrx Pharmaceuticals, Inc. Once daily pharmaceutical tablet having a unitary core

Also Published As

Publication number Publication date
CA2315329A1 (en) 1999-06-24
JP2002508311A (ja) 2002-03-19
JP2010229150A (ja) 2010-10-14
JP5132721B2 (ja) 2013-01-30
EP1035842B1 (de) 2005-10-26
ATE307572T1 (de) 2005-11-15
EP1035842A1 (de) 2000-09-20
EP1035842A4 (de) 2003-07-23
ES2252872T3 (es) 2006-05-16
US5916595A (en) 1999-06-29
WO1999030692A1 (en) 1999-06-24
AU737962B2 (en) 2001-09-06
AU1627599A (en) 1999-07-05
JP4646400B2 (ja) 2011-03-09
DE69832092T2 (de) 2006-07-13
CA2315329C (en) 2008-04-29

Similar Documents

Publication Publication Date Title
DE69832092D1 (de) VERBESSERTE HMG CoA REDUKTASE-INHIBITOR FORMULIERUNG MIT VERLÄNGERTER FREISETZUNG
ATE287260T1 (de) Formulierung mit einer vorgeformten öffnung zur gesteuerten freisetzung
BR9806174A (pt) Péletes tendo um núcleo revestido com um antifúngico e um polìmero
EP0815853A3 (de) Langsam freisetzende Zubereitung für bioaktive Substanz mit einer sauren Gruppe
SV1998000104A (es) Formas de dosificacion farmaceuticas solidas
ES2094694B1 (es) Nueva formulacion farmaceuticamente estable de un compuesto de bencimidazol y su proceso de obtencion.
DE69907977D1 (de) Pyrrolobenzodiazepine
PT801560E (pt) Um dispositivo de libertacao controlada de um farmaco em suspensao
AU2016992A (en) Multi-layered controlled release formulation
LU91122I2 (fr) Efalizumab et ses dérivés pharmaceutiquement acceptables (raptiva).
ME00391B (me) Tableta bupropion hidrohlorida sa modifikovanim otpuštanjem
ES2175362T3 (es) Agente fitosanitario solido.
ATE238813T1 (de) Wirkstoffformulierungen mit verzögerter freisetzung
DE69109286D1 (de) Pharmazeutische zusammensetzung.
KR930003905A (ko) 약학적 결합 제제
ATE243026T1 (de) Bupropion-darreichungsform mit kontrollierter freisetzung
WO2002024174A3 (en) Sustained release composition containing clarithromycin
AU7562896A (en) Water soluble films
ES2196381T3 (es) Comprimidos chupables para liberacion modificada de principios activos en el tracto gastrointestinal.
BR0108753A (pt) Corpos sólidos
PT1263745E (pt) 3-fenil-5-alcoxi-1,3,4-oxadiazol-2-onas substituidas e sua utilizacao para a inibicao da lipase sensivel a hormonas
ATE306254T1 (de) Zubereitungen mit verbesserter kontrollierter freisetzung
ATE273002T1 (de) Feste lösung eines fungizids mit erhöhter bioverfügbarkeit
IT1320867B1 (it) Polimero organico per rivestimento antiriflesso e sua preparazione.
AU5703298A (en) Soluble polymer based matrix for chemically active water insoluble components

Legal Events

Date Code Title Description
8364 No opposition during term of opposition